In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment ... was approved in several countries to treat eligible patients with ...
For example, the FDA-approved CRISPR-Cas9-based therapy Casgevy, designed to treat sickle cell disease, provides life-changing potential but comes at a staggering one-time cost of $2.2 million.
Liverpool secured themselves a top-eight league phase finish with their 2-1 win over LOSC Lille at Anfield on Tuesday, which also earned the Reds millions in prize money. The Merseyside squad are now ...